Duration of effects of isradipine during twice daily therapy in angina pectoris View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1994-04

AUTHORS

Udho Thadani, Steven Chrysant, Jeffrey Gorwit, Thomas Giles, Stephen Archer, Bruce Iteld, Steven Singh, David Copen, Charles Wakeford, Stuart Hobbs

ABSTRACT

Isradipine, a 1,4 dihydropyridine calcium channel antagonist, is a potent coronary artery dilator that increases coronary blood flow with little effect on cardiac contractility. Isradipine is an approved antihypertensive agent, but its antianginal effects have not been well documented. In this placebo-controlled, double-blind, parallel-group design study we evaluated the duration of effects and safety of isradipine 10 mg bid in male patients with chronic stable angina pectoris. Seventy-two patients experiencing moderately severe angina between 3 and 7.5 minutes during a standard Bruce exercise test received placebo in a single-blind manner for 8-14 days. Sixty-one of these patients had reproducible treadmill exercise test results on three consecutive occasions and underwent further exercise tests at 3, 8, and 12 hours after a placebo period. Patients were then randomized (double blind) to either placebo or isradipine 10 mg bid for 2 weeks. Symptom-limited exercise tests were repeated predose and at 3, 8, and 12 hours after the 0800 hour dose dosing. Exercise duration increased significantly from baseline (last qualifying test during the single-blind placebo therapy, i.e., 0800 hours predose at visit 4) in the isradipine group compared to the placebo group prior to the administration of the 0800 hour dose (i.e., 12 hours after the 2000 hour dose) by 51 vs. 18 seconds, p = 0.04; and after the administration of the 0800 hour dose at 3 hours by 78 vs. 29 seconds, p = 0.005; and at 8 hours by 54 vs. 18 seconds, p = 0.04. Similarly, statistical significance was achieved when exercise data were analyzed using visit 4 (single-blind placebo therapy) corresponding time points as baseline. At 12 hours after the 0800 hour dose, exercise tolerance did not increase significantly after isradipine compared to placebo. Time to 1-mm ST-segment depression increased significantly after isradipine at 3 hours post 0800 hour dose compared to placebo (87 vs. 7 seconds, p < 0.01) but not at the 0, 8, or 12-hour postdose time points, regardless of which baseline was used. Isradipine therapy did not affect the rate-pressure double product. A significant correlation between the mean increase in total exercise time and mean plasma isradipine concentration was also present (p = 0.0295). During double-blind treatment, drug-related adverse events were experienced by four patients in the isradipine group and two patients in the placebo group. None of the patients experienced ischemic complications during the study.(ABSTRACT TRUNCATED AT 400 WORDS) More... »

PAGES

199-210

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00877328

DOI

http://dx.doi.org/10.1007/bf00877328

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036702515

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/7918132


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angina Pectoris", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemistry, Pharmaceutical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Electrocardiography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Exercise Test", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Isradipine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitroglycerin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Placebos", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Single-Blind Method", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Oklahoma", 
          "id": "https://www.grid.ac/institutes/grid.266900.b", 
          "name": [
            "University of Oklahoma and VA Medical Center, Health Sciences Center, Oklahoma City, Oklahoma"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thadani", 
        "givenName": "Udho", 
        "id": "sg:person.01334373730.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334373730.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Oklahoma Cardiac and Hypertensive Center, Oklahoma City, Oklahoma"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chrysant", 
        "givenName": "Steven", 
        "id": "sg:person.01072477732.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072477732.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Escondido Cardiology Associate, Escondido, California"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gorwit", 
        "givenName": "Jeffrey", 
        "id": "sg:person.07643136634.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07643136634.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tulane Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.412823.e", 
          "name": [
            "Tulane Medical Center, New Orleans, Louisiana"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giles", 
        "givenName": "Thomas", 
        "id": "sg:person.01117611063.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117611063.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Minneapolis VA Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.491585.4", 
          "name": [
            "VA Medical Center, Minneapolis, Minnesota"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Archer", 
        "givenName": "Stephen", 
        "id": "sg:person.01177101513.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177101513.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Chalmette, Louisiana"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iteld", 
        "givenName": "Bruce", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Washington DC VA Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.413721.2", 
          "name": [
            "VA Medical Center, Washington, DC"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Singh", 
        "givenName": "Steven", 
        "id": "sg:person.01017235514.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017235514.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Danbury Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413451.6", 
          "name": [
            "Danbury Hospital, Danbury, Connecticut"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Copen", 
        "givenName": "David", 
        "id": "sg:person.012623526221.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012623526221.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Glaxo Research Institute, Research Triangle Park, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wakeford", 
        "givenName": "Charles", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Glaxo Research Institute, Research Triangle Park, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hobbs", 
        "givenName": "Stuart", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/0002-9149(89)91073-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000628941"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.84.6.2398", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003862391"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0002-9343(88)90182-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005138215"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/j.1552-4604.1988.tb03098.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007646585"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0002-9149(90)90083-d", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007655090"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0167-5273(88)90026-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010367143"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00005344-198501000-00030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015031260"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00005344-198501000-00030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015031260"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0002-9149(87)90079-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016178745"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0002-9343(88)90190-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016871702"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0002-9149(87)90091-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019261331"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0002-9343(88)80075-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027267870"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00543970", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029246807", 
          "https://doi.org/10.1007/bf00543970"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00543970", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029246807", 
          "https://doi.org/10.1007/bf00543970"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00005344-198405000-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033466096"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00005344-198405000-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033466096"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0033-0620(69)90027-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033628205"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.84.6.2598", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035132770"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0002-9343(89)90201-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035607464"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1986.246", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036545864", 
          "https://doi.org/10.1038/clpt.1986.246"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archinte.1991.00400020026007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039381511"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02125752", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042137730", 
          "https://doi.org/10.1007/bf02125752"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02125752", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042137730", 
          "https://doi.org/10.1007/bf02125752"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0002-9343(88)90193-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044907796"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0002-9343(89)90195-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047514157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00005344-198909000-00020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050164836"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00005344-198909000-00020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050164836"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00549587", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051453215", 
          "https://doi.org/10.1007/bf00549587"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00549587", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051453215", 
          "https://doi.org/10.1007/bf00549587"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/clc.4960120709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052079230"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1994-04", 
    "datePublishedReg": "1994-04-01", 
    "description": "Isradipine, a 1,4 dihydropyridine calcium channel antagonist, is a potent coronary artery dilator that increases coronary blood flow with little effect on cardiac contractility. Isradipine is an approved antihypertensive agent, but its antianginal effects have not been well documented. In this placebo-controlled, double-blind, parallel-group design study we evaluated the duration of effects and safety of isradipine 10 mg bid in male patients with chronic stable angina pectoris. Seventy-two patients experiencing moderately severe angina between 3 and 7.5 minutes during a standard Bruce exercise test received placebo in a single-blind manner for 8-14 days. Sixty-one of these patients had reproducible treadmill exercise test results on three consecutive occasions and underwent further exercise tests at 3, 8, and 12 hours after a placebo period. Patients were then randomized (double blind) to either placebo or isradipine 10 mg bid for 2 weeks. Symptom-limited exercise tests were repeated predose and at 3, 8, and 12 hours after the 0800 hour dose dosing. Exercise duration increased significantly from baseline (last qualifying test during the single-blind placebo therapy, i.e., 0800 hours predose at visit 4) in the isradipine group compared to the placebo group prior to the administration of the 0800 hour dose (i.e., 12 hours after the 2000 hour dose) by 51 vs. 18 seconds, p = 0.04; and after the administration of the 0800 hour dose at 3 hours by 78 vs. 29 seconds, p = 0.005; and at 8 hours by 54 vs. 18 seconds, p = 0.04. Similarly, statistical significance was achieved when exercise data were analyzed using visit 4 (single-blind placebo therapy) corresponding time points as baseline. At 12 hours after the 0800 hour dose, exercise tolerance did not increase significantly after isradipine compared to placebo. Time to 1-mm ST-segment depression increased significantly after isradipine at 3 hours post 0800 hour dose compared to placebo (87 vs. 7 seconds, p < 0.01) but not at the 0, 8, or 12-hour postdose time points, regardless of which baseline was used. Isradipine therapy did not affect the rate-pressure double product. A significant correlation between the mean increase in total exercise time and mean plasma isradipine concentration was also present (p = 0.0295). During double-blind treatment, drug-related adverse events were experienced by four patients in the isradipine group and two patients in the placebo group. None of the patients experienced ischemic complications during the study.(ABSTRACT TRUNCATED AT 400 WORDS)", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00877328", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1097576", 
        "issn": [
          "0920-3206", 
          "1573-7241"
        ], 
        "name": "Cardiovascular Drugs and Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "name": "Duration of effects of isradipine during twice daily therapy in angina pectoris", 
    "pagination": "199-210", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "aed66b936dce40fb123cfae0b4880fce7db255ae402d1582af8da81ec917d01f"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "7918132"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8712220"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00877328"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036702515"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00877328", 
      "https://app.dimensions.ai/details/publication/pub.1036702515"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000490.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00877328"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00877328'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00877328'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00877328'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00877328'


 

This table displays all metadata directly associated to this object as RDF triples.

287 TRIPLES      21 PREDICATES      68 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00877328 schema:about N0ea4d59a21d84ccd9ccf2915bba96f4f
2 N121b12124a27439283a541e3d6e95c4a
3 N24a339b66cf2412abf6678a2a2097a48
4 N377dfdee58774fb1bcb355cfb24d0670
5 N4ceab46e8a1f4dd48a9ddf375c5eb6a0
6 N590f19c1883b4791a4e12df2679e1c62
7 N652e0516c0c041b3b1d1136212123995
8 N6df77c6e1fe243dcbc4683103401355b
9 N6ebd1debb8024ed191cb0e9be903f90d
10 N7ced6dca12424d1093ef6898b0be8abd
11 N9905b63473a64505ac4e3aba9dceabff
12 Na2b3c916d8834fe4b02058970cd363c2
13 Na2ff3397752c45c8965d4522db1ef7f8
14 Nbe031dd45c604d61a1f7055a221a5b60
15 Ncd3ea34e52e340c8a1db0dc3d207bfea
16 anzsrc-for:11
17 anzsrc-for:1102
18 schema:author N1b300787797b4365a8398d4ef7f1f5d8
19 schema:citation sg:pub.10.1007/bf00543970
20 sg:pub.10.1007/bf00549587
21 sg:pub.10.1007/bf02125752
22 sg:pub.10.1038/clpt.1986.246
23 https://doi.org/10.1001/archinte.1991.00400020026007
24 https://doi.org/10.1002/clc.4960120709
25 https://doi.org/10.1002/j.1552-4604.1988.tb03098.x
26 https://doi.org/10.1016/0002-9149(87)90079-8
27 https://doi.org/10.1016/0002-9149(87)90091-9
28 https://doi.org/10.1016/0002-9149(89)91073-4
29 https://doi.org/10.1016/0002-9149(90)90083-d
30 https://doi.org/10.1016/0002-9343(88)90182-9
31 https://doi.org/10.1016/0002-9343(88)90190-8
32 https://doi.org/10.1016/0002-9343(88)90193-3
33 https://doi.org/10.1016/0002-9343(89)90195-2
34 https://doi.org/10.1016/0002-9343(89)90201-5
35 https://doi.org/10.1016/0033-0620(69)90027-9
36 https://doi.org/10.1016/0167-5273(88)90026-5
37 https://doi.org/10.1016/s0002-9343(88)80075-5
38 https://doi.org/10.1097/00005344-198405000-00005
39 https://doi.org/10.1097/00005344-198501000-00030
40 https://doi.org/10.1097/00005344-198909000-00020
41 https://doi.org/10.1161/01.cir.84.6.2398
42 https://doi.org/10.1161/01.cir.84.6.2598
43 schema:datePublished 1994-04
44 schema:datePublishedReg 1994-04-01
45 schema:description Isradipine, a 1,4 dihydropyridine calcium channel antagonist, is a potent coronary artery dilator that increases coronary blood flow with little effect on cardiac contractility. Isradipine is an approved antihypertensive agent, but its antianginal effects have not been well documented. In this placebo-controlled, double-blind, parallel-group design study we evaluated the duration of effects and safety of isradipine 10 mg bid in male patients with chronic stable angina pectoris. Seventy-two patients experiencing moderately severe angina between 3 and 7.5 minutes during a standard Bruce exercise test received placebo in a single-blind manner for 8-14 days. Sixty-one of these patients had reproducible treadmill exercise test results on three consecutive occasions and underwent further exercise tests at 3, 8, and 12 hours after a placebo period. Patients were then randomized (double blind) to either placebo or isradipine 10 mg bid for 2 weeks. Symptom-limited exercise tests were repeated predose and at 3, 8, and 12 hours after the 0800 hour dose dosing. Exercise duration increased significantly from baseline (last qualifying test during the single-blind placebo therapy, i.e., 0800 hours predose at visit 4) in the isradipine group compared to the placebo group prior to the administration of the 0800 hour dose (i.e., 12 hours after the 2000 hour dose) by 51 vs. 18 seconds, p = 0.04; and after the administration of the 0800 hour dose at 3 hours by 78 vs. 29 seconds, p = 0.005; and at 8 hours by 54 vs. 18 seconds, p = 0.04. Similarly, statistical significance was achieved when exercise data were analyzed using visit 4 (single-blind placebo therapy) corresponding time points as baseline. At 12 hours after the 0800 hour dose, exercise tolerance did not increase significantly after isradipine compared to placebo. Time to 1-mm ST-segment depression increased significantly after isradipine at 3 hours post 0800 hour dose compared to placebo (87 vs. 7 seconds, p < 0.01) but not at the 0, 8, or 12-hour postdose time points, regardless of which baseline was used. Isradipine therapy did not affect the rate-pressure double product. A significant correlation between the mean increase in total exercise time and mean plasma isradipine concentration was also present (p = 0.0295). During double-blind treatment, drug-related adverse events were experienced by four patients in the isradipine group and two patients in the placebo group. None of the patients experienced ischemic complications during the study.(ABSTRACT TRUNCATED AT 400 WORDS)
46 schema:genre research_article
47 schema:inLanguage en
48 schema:isAccessibleForFree false
49 schema:isPartOf N767e6b1c4b0a45ba8650460d48dbc5bb
50 Nf6a40e08fbb44a688f4887765016ce83
51 sg:journal.1097576
52 schema:name Duration of effects of isradipine during twice daily therapy in angina pectoris
53 schema:pagination 199-210
54 schema:productId N4eca1e7646f2408a9bd107dbde64f15a
55 N5e7071c336cc4d98af1174a47553b1d1
56 N67ad3d45521d4b749fa521f7f251c3f7
57 N910f2aac0a0648d29bd17a4f29953861
58 Nb83286df8430420db55b0cdccd2e61c5
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036702515
60 https://doi.org/10.1007/bf00877328
61 schema:sdDatePublished 2019-04-10T16:37
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher N6e5944d8d5464fa39faac8d1a1c5fd5d
64 schema:url http://link.springer.com/10.1007/BF00877328
65 sgo:license sg:explorer/license/
66 sgo:sdDataset articles
67 rdf:type schema:ScholarlyArticle
68 N05658d49f42840a69865ce70ebdf79d1 rdf:first N0dab7794df3e4e4e8b70a1502a0e0058
69 rdf:rest N4b2cee4feaac46b4a983c4efa4590da7
70 N0b5e9f4baad24df6a04d22fc75e0d7c4 rdf:first sg:person.07643136634.54
71 rdf:rest N65ea9bb25a244d149487c31f89260dcf
72 N0dab7794df3e4e4e8b70a1502a0e0058 schema:affiliation N0f0481a34f31403d93a6ab55dd631549
73 schema:familyName Iteld
74 schema:givenName Bruce
75 rdf:type schema:Person
76 N0ea4d59a21d84ccd9ccf2915bba96f4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Humans
78 rdf:type schema:DefinedTerm
79 N0f0481a34f31403d93a6ab55dd631549 schema:name Chalmette, Louisiana
80 rdf:type schema:Organization
81 N121b12124a27439283a541e3d6e95c4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Isradipine
83 rdf:type schema:DefinedTerm
84 N1b300787797b4365a8398d4ef7f1f5d8 rdf:first sg:person.01334373730.38
85 rdf:rest N57bd370b291d4936885c801fb6cc2908
86 N1cb4c0beef984d9f9f3dcf654aaa7acf rdf:first Ne5c4f70f007940bfbe5bbc273b6a0776
87 rdf:rest rdf:nil
88 N24a339b66cf2412abf6678a2a2097a48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Male
90 rdf:type schema:DefinedTerm
91 N377dfdee58774fb1bcb355cfb24d0670 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Middle Aged
93 rdf:type schema:DefinedTerm
94 N395e6639b2484d8d9ed3eb3dd6cab1b5 schema:name Escondido Cardiology Associate, Escondido, California
95 rdf:type schema:Organization
96 N4915e897cacb47eaa82fce526dbbb248 schema:name Glaxo Research Institute, Research Triangle Park, North Carolina, USA
97 rdf:type schema:Organization
98 N4b2cee4feaac46b4a983c4efa4590da7 rdf:first sg:person.01017235514.30
99 rdf:rest N8db075dcde054b65926e59f1f3b6bb9f
100 N4ceab46e8a1f4dd48a9ddf375c5eb6a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Single-Blind Method
102 rdf:type schema:DefinedTerm
103 N4eca1e7646f2408a9bd107dbde64f15a schema:name doi
104 schema:value 10.1007/bf00877328
105 rdf:type schema:PropertyValue
106 N57bd370b291d4936885c801fb6cc2908 rdf:first sg:person.01072477732.04
107 rdf:rest N0b5e9f4baad24df6a04d22fc75e0d7c4
108 N590f19c1883b4791a4e12df2679e1c62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Angina Pectoris
110 rdf:type schema:DefinedTerm
111 N5e7071c336cc4d98af1174a47553b1d1 schema:name pubmed_id
112 schema:value 7918132
113 rdf:type schema:PropertyValue
114 N652e0516c0c041b3b1d1136212123995 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Nitroglycerin
116 rdf:type schema:DefinedTerm
117 N65ea9bb25a244d149487c31f89260dcf rdf:first sg:person.01117611063.57
118 rdf:rest Nfd006e5b618e4d4fa43a4b66717dd518
119 N67ad3d45521d4b749fa521f7f251c3f7 schema:name dimensions_id
120 schema:value pub.1036702515
121 rdf:type schema:PropertyValue
122 N6df77c6e1fe243dcbc4683103401355b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Aged
124 rdf:type schema:DefinedTerm
125 N6e5944d8d5464fa39faac8d1a1c5fd5d schema:name Springer Nature - SN SciGraph project
126 rdf:type schema:Organization
127 N6ebd1debb8024ed191cb0e9be903f90d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Placebos
129 rdf:type schema:DefinedTerm
130 N767e6b1c4b0a45ba8650460d48dbc5bb schema:volumeNumber 8
131 rdf:type schema:PublicationVolume
132 N7ced6dca12424d1093ef6898b0be8abd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Electrocardiography
134 rdf:type schema:DefinedTerm
135 N80bf8c70e2154a959905dac3d3fa67d0 schema:name Glaxo Research Institute, Research Triangle Park, North Carolina, USA
136 rdf:type schema:Organization
137 N82e48e21e91a4b69916f7a40d2c0f5f2 rdf:first Ne6bb102a071448c58eae92d057d3985b
138 rdf:rest N1cb4c0beef984d9f9f3dcf654aaa7acf
139 N8db075dcde054b65926e59f1f3b6bb9f rdf:first sg:person.012623526221.34
140 rdf:rest N82e48e21e91a4b69916f7a40d2c0f5f2
141 N910f2aac0a0648d29bd17a4f29953861 schema:name readcube_id
142 schema:value aed66b936dce40fb123cfae0b4880fce7db255ae402d1582af8da81ec917d01f
143 rdf:type schema:PropertyValue
144 N9905b63473a64505ac4e3aba9dceabff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Adult
146 rdf:type schema:DefinedTerm
147 Na2b3c916d8834fe4b02058970cd363c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Chemistry, Pharmaceutical
149 rdf:type schema:DefinedTerm
150 Na2ff3397752c45c8965d4522db1ef7f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Drug Administration Schedule
152 rdf:type schema:DefinedTerm
153 Nb83286df8430420db55b0cdccd2e61c5 schema:name nlm_unique_id
154 schema:value 8712220
155 rdf:type schema:PropertyValue
156 Nbe031dd45c604d61a1f7055a221a5b60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Exercise Test
158 rdf:type schema:DefinedTerm
159 Ncd3ea34e52e340c8a1db0dc3d207bfea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Double-Blind Method
161 rdf:type schema:DefinedTerm
162 Ne5c4f70f007940bfbe5bbc273b6a0776 schema:affiliation N4915e897cacb47eaa82fce526dbbb248
163 schema:familyName Hobbs
164 schema:givenName Stuart
165 rdf:type schema:Person
166 Ne6bb102a071448c58eae92d057d3985b schema:affiliation N80bf8c70e2154a959905dac3d3fa67d0
167 schema:familyName Wakeford
168 schema:givenName Charles
169 rdf:type schema:Person
170 Nf6a40e08fbb44a688f4887765016ce83 schema:issueNumber 2
171 rdf:type schema:PublicationIssue
172 Nf8beb19b798e4124a21f90b31ab7251f schema:name Oklahoma Cardiac and Hypertensive Center, Oklahoma City, Oklahoma
173 rdf:type schema:Organization
174 Nfd006e5b618e4d4fa43a4b66717dd518 rdf:first sg:person.01177101513.69
175 rdf:rest N05658d49f42840a69865ce70ebdf79d1
176 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
177 schema:name Medical and Health Sciences
178 rdf:type schema:DefinedTerm
179 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
180 schema:name Cardiorespiratory Medicine and Haematology
181 rdf:type schema:DefinedTerm
182 sg:journal.1097576 schema:issn 0920-3206
183 1573-7241
184 schema:name Cardiovascular Drugs and Therapy
185 rdf:type schema:Periodical
186 sg:person.01017235514.30 schema:affiliation https://www.grid.ac/institutes/grid.413721.2
187 schema:familyName Singh
188 schema:givenName Steven
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017235514.30
190 rdf:type schema:Person
191 sg:person.01072477732.04 schema:affiliation Nf8beb19b798e4124a21f90b31ab7251f
192 schema:familyName Chrysant
193 schema:givenName Steven
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072477732.04
195 rdf:type schema:Person
196 sg:person.01117611063.57 schema:affiliation https://www.grid.ac/institutes/grid.412823.e
197 schema:familyName Giles
198 schema:givenName Thomas
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117611063.57
200 rdf:type schema:Person
201 sg:person.01177101513.69 schema:affiliation https://www.grid.ac/institutes/grid.491585.4
202 schema:familyName Archer
203 schema:givenName Stephen
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177101513.69
205 rdf:type schema:Person
206 sg:person.012623526221.34 schema:affiliation https://www.grid.ac/institutes/grid.413451.6
207 schema:familyName Copen
208 schema:givenName David
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012623526221.34
210 rdf:type schema:Person
211 sg:person.01334373730.38 schema:affiliation https://www.grid.ac/institutes/grid.266900.b
212 schema:familyName Thadani
213 schema:givenName Udho
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334373730.38
215 rdf:type schema:Person
216 sg:person.07643136634.54 schema:affiliation N395e6639b2484d8d9ed3eb3dd6cab1b5
217 schema:familyName Gorwit
218 schema:givenName Jeffrey
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07643136634.54
220 rdf:type schema:Person
221 sg:pub.10.1007/bf00543970 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029246807
222 https://doi.org/10.1007/bf00543970
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/bf00549587 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051453215
225 https://doi.org/10.1007/bf00549587
226 rdf:type schema:CreativeWork
227 sg:pub.10.1007/bf02125752 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042137730
228 https://doi.org/10.1007/bf02125752
229 rdf:type schema:CreativeWork
230 sg:pub.10.1038/clpt.1986.246 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036545864
231 https://doi.org/10.1038/clpt.1986.246
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1001/archinte.1991.00400020026007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039381511
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1002/clc.4960120709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052079230
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1002/j.1552-4604.1988.tb03098.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1007646585
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1016/0002-9149(87)90079-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016178745
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1016/0002-9149(87)90091-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019261331
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1016/0002-9149(89)91073-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000628941
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1016/0002-9149(90)90083-d schema:sameAs https://app.dimensions.ai/details/publication/pub.1007655090
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1016/0002-9343(88)90182-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005138215
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1016/0002-9343(88)90190-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016871702
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1016/0002-9343(88)90193-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044907796
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1016/0002-9343(89)90195-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047514157
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1016/0002-9343(89)90201-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035607464
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1016/0033-0620(69)90027-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033628205
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1016/0167-5273(88)90026-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010367143
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1016/s0002-9343(88)80075-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027267870
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1097/00005344-198405000-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033466096
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1097/00005344-198501000-00030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015031260
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1097/00005344-198909000-00020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050164836
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1161/01.cir.84.6.2398 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003862391
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1161/01.cir.84.6.2598 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035132770
272 rdf:type schema:CreativeWork
273 https://www.grid.ac/institutes/grid.266900.b schema:alternateName University of Oklahoma
274 schema:name University of Oklahoma and VA Medical Center, Health Sciences Center, Oklahoma City, Oklahoma
275 rdf:type schema:Organization
276 https://www.grid.ac/institutes/grid.412823.e schema:alternateName Tulane Medical Center
277 schema:name Tulane Medical Center, New Orleans, Louisiana
278 rdf:type schema:Organization
279 https://www.grid.ac/institutes/grid.413451.6 schema:alternateName Danbury Hospital
280 schema:name Danbury Hospital, Danbury, Connecticut
281 rdf:type schema:Organization
282 https://www.grid.ac/institutes/grid.413721.2 schema:alternateName Washington DC VA Medical Center
283 schema:name VA Medical Center, Washington, DC
284 rdf:type schema:Organization
285 https://www.grid.ac/institutes/grid.491585.4 schema:alternateName Minneapolis VA Medical Center
286 schema:name VA Medical Center, Minneapolis, Minnesota
287 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...